|CD306||LAIR-2 (leukocyte associated immunoglobulin-like receptor 2)|
|Molecule Type||Antigen Expression||Molecular Weight|
Min / Max
|Non-lineage Restricted Molecule|
Type 1 glycoprotein
|Putative Secreted Protein|
|16 / 16|
|CD306 is expressed on monocytes, T cells and putative secreted proteins.|
|MOLECULAR FAMILY NAME: Belongs to the immunoglobulin gene family.|
CD306 is a single-pass type-1 152 aa glycoprotein. It contains an extracellular domain which contains an Ig-like 2-type domain and a potential N-glycosylation site but it lacks a transmembrane domain and cytoplasmic domains. CD306 was first identified by its similarity to CD305 (LAIR-1) which show 84% homology. CD306 is an inhibitory receptor present on mononuclear leukocytes.
Alternative splicing yields 2 different isoforms. The isoforms lack the transmembrane domain and cytoplasmic domain suggesting that they are soluble or attached to the membrane indirectly.
CD306 has a potential N-glycosylation site.
|LIGANDS AND MOLECULE ASSOCIATED WITH CD306|
CD306 is associated with Ep-CAM.
|The function of CD306 is unknown but it has been suggested that it is a secreted protein form of CD305 and may help modulate mucosal tolerance. CD306 is thought to inhibit cellular activation and inflammation. |
BIOCHEMICAL ACTIVITY: No information.
DISEASE RELEVANCE AND FUNCTION OF CD306 IN INTACT ANIMAL: No information.
PROTEINS AND DNA ELEMENTS WHICH REGULATE TRANSCRIPTION OF CD306: No information.
SUBSTRATES: No information.
ENZYMES WHICH MODIFY CD306: No information.
For further information see Meyaards, L. et al (1997) Immunity 7: 283-290.
Database accession numbers
Revised June 25, 2008